Nanoformulated Zoledronic Acid Boosts the Vδ2 T Cell Immunotherapeutic Potential in Colorectal Cancer
Open Access
Abstract
Aminobisphosphonates, such as zoledronic acid (ZA), have shown potential in the treatment of different malignancies, including colorectal carcinoma (CRC). Yet, their clinical exploitation is limited by their high bone affinity and modest bioavailability. Here, ZA is encapsulated into the aqueous core of spherical polymeric nanoparticles (SPNs), whose size and architecture resemble that of biological vesicles. On Vδ2 T cells, derived from the peripheral blood of healthy donors and CRC patients, ZA-SPNs induce proliferation and trigger activation up to three orders of magnitude more efficiently than soluble ZA. These activated Vδ2 T cells kill CRC cells and tumor spheroids, and are able to migrate toward CRC cells in a microfluidic system. Notably, ZA-SPNs can also stimulate the proliferation of Vδ2 T cells from the tumor-infiltrating lymphocytes of CRC patients and boost their cytotoxic activity against patients’ autologous tumor organoids. These data represent a first step toward the use of nanoformulated ZA for immunotherapy in CRC patients.Keywords
Funding Information
- Associazione Italiana per la Ricerca sul Cancro (IG 17664 to PD IG 21648 to AP)
- Fondazione San Paolo (Ligurian Alliance for Nanomedicine against cancer)
- Ministero della Salute and Ricerca Corrente 2018-2021 (5xmille 2014, 5xmille2015, 5xmille2016)
- European Union’s Seventh Framework Programme (ERC 616695 to PD)
This publication has 66 references indexed in Scilit:
- Butyrophilin 3A1 binds phosphorylated antigens and stimulates human γδ T cellsNature Immunology, 2013
- Indirect Stimulation of Human Vγ2Vδ2 T Cells through Alterations in Isoprenoid MetabolismThe Journal of Immunology, 2011
- Pilot trial of interleukin-2 and zoledronic acid to augment γδ T cells as treatment for patients with refractory renal cell carcinomaCancer Immunology, Immunotherapy, 2011
- Adoptive Immunotherapy for Advanced Non-small Cell Lung Cancer Using Zoledronate-expanded γδ T CellsJournal of Immunotherapy, 2011
- Relevance of the mevalonate biosynthetic pathway in the regulation of bone marrow mesenchymal stromal cell-mediated effects on T-cell proliferation and B-cell survivalHaematologica, 2010
- Phosphoantigens Overcome Human TCRVγ9+ γδ Cell Immunosuppression by TGF-β: Relevance for Cancer ImmunotherapyThe Journal of Immunology, 2010
- In vivo manipulation of Vγ9Vδ2 T cells with zoledronate and low-dose interleukin-2 for immunotherapy of advanced breast cancer patientsClinical and Experimental Immunology, 2010
- γδ T Cells and the Lymphoid Stress-Surveillance ResponseImmunity, 2009
- In vitro expansion of gamma delta T cells with anti‐myeloma cell activity by Phosphostim and IL‐2 in patients with multiple myelomaBritish Journal of Haematology, 2007
- Human T Cell Receptor γδ Cells Recognize Endogenous Mevalonate Metabolites in Tumor CellsJournal of Experimental Medicine, 2003